NCT06682767Not yet recruitingPhase 1/2
A Nutritional and Pharmacological Intervention for Body, Brain, and Longevity Effects (NIBBLE)
A Nutritional and Pharmacological Intervention for Body, Brain, and Longevity Effects (NIBBLE) - A Randomized Open-label Intervention of the Fasting-mimicking Diet (FMD) and Rapamycin (NIBBLE)
Source: ClinicalTrials.gov · Last updated 16 Sept 2026
Brief summary (registry, in English)
The study aims to evaluate the safety, feasibility, and preliminary efficacy of the fasting-mimicking diet (FMD) or low-dose daily rapamycin treatment relative to a matched placebo control group when administered over 8 weeks in middle-aged adults at elevated risk for Alzheimer's disease due to the apolipoprotein (APOE) ε4 allele. Participants randomly assigned to the FMD intervention will adhere to FMD for 5-days over three cycles for a period of approximately 8 weeks. Participants randomly assigned to the rapamycin and placebo groups will take 1 mg of rapamycin or a matched placebo pill daily for approximately 8 weeks.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 29 Oct 2024
- Start date
- Nov 2026
- Primary completion date
- Mar 2028
- Lead sponsor
- Cedars-Sinai Medical Center
- Diseases
- Alzheimer disease
- NCT number
- NCT06682767
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 60
- From Nov 2026 to the primary completion date, Mar 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Small or large bowel resection
- Subjects with recent weight loss (\>5%), use of weight loss medication, participated in a weight loss program in the past 3 months
- Use of immune suppression drugs;
- Women who are on hormone replacement therapy
- Required use of drugs that affect cytochrome P450 3A4 or alter cerebral blood flow (see Appendix 1 for tables of excluded medications)
Other illness
- Has any medical disease or condition that, in the opinion of the principal investigator (PI) or appropriate study personnel, precludes study participation\* (\*Including acute, subacute, intermittent or chronic medical disease or condition that would place the subject at an unacceptable risk of injury, render the subject unable to meet the requirements of the protocol, or may interfere with the evaluation of responses or the subject's successful completion of this trial);
- Diagnosis of a significant neurological condition such as multiple sclerosis, epilepsy, Parkinson's disease, major stroke
- Contraindications to MRI such as claustrophobia, cardiac pacemaker, etc.
- Food allergies (e.g. dairy, eggs, fish/shellfish, peanuts, tree nuts, soy, wheat, sesame, corn)
- Diagnosis of mild cognitive impairment or dementia; use of an FDA-approved medication for Alzheimer's disease; MoCA\<23
- History of gastric bypass;
- Inflammatory bowel disease
- Contraindication for study foods (special food needs and allergy);
- Active malignant cancer or history of malignancy within the last 1 yea1s (except non-melanoma skin cancer)
- Serious psychiatric disorders such as schizophrenia, bipolar disorder, eating disorders
- Persons with allergy to animal dander or animal-instigated asthma
- Current or chronic liver, kidney, cardiac, or pulmonary diseases
Lab values
- Diabetes (hbA1c \>6.5%) or anti-diabetic medications
- Untreated hypertriglyceridemia (fasting triglycerides \> 300 mg/dl)
Other
- Significant depression (PHQ-9\>9) or generalized anxiety (GAD-7\>9)
- Current adherence or adherence within the past 3 months to a specialized diet (e.g. ketogenic, paleo, intermittent fasting, raw food, vegan)
- Women who are pregnant, lactating, or trying to conceive
- Alcohol dependency (alcohol intake greater than two drinks per day for women and three drinks per day for men)
- Current smoker or tobacco use within 3 months.
- Poorly controlled blood pressure (systolic BP \> 160 or diastolic BP \> 100 mmHg
Who the study is looking for
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Male or female, aged 45-65 years at screening
- Carrier of at least one copy of the APOE e4 allele
- BMI 20-39kg/m2 (inclusive) at screening
- On a stable medication regimen for at least 3 months.
- For females: Post-menopausal status or use of highly effective contraception.
Age in the registry: 45 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cedars-Sinai Medical Center Coordinator of this site? Confirm its status | Los Angeles | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.